Back to Search Start Over

A case of secondary adrenocortical insufficiency due to isolated adrenocorticotropic hormone deficiency with empty sella syndrome after pembrolizumab treatment in a patient with metastatic renal pelvic cancer

Authors :
Nami Tomiyama
Takashi Nagai
Takahiro Yasui
Tomoki Takeda
Tohru Mogami
Source :
Urology Case Reports, Vol 39, Iss, Pp 101766-(2021), Urology Case Reports
Publication Year :
2021
Publisher :
Elsevier, 2021.

Abstract

Pembrolizumab, an anti-programmed death-1 specific monoclonal antibody is a second-line treatment for metastatic urothelial carcinoma. Physicians should be aware of adverse immune-related events associated with the use of immune checkpoint inhibitors, particularly adrenocortical insufficiency, which poses a risk of death. We report a case of secondary adrenocortical insufficiency due to isolated adrenocorticotropic hormone deficiency with empty sella syndrome after pembrolizumab treatment in a patient with metastatic renal pelvic cancer. Fortunately, a therapeutic effect was observed 4 months after discontinuation of pembrolizumab, and a durable antitumor response has persisted for 5 months.

Details

Language :
English
ISSN :
22144420
Volume :
39
Database :
OpenAIRE
Journal :
Urology Case Reports
Accession number :
edsair.doi.dedup.....bc3d6bc4e920b12d4dc775f6fc6b30ac